Salvage Chemotherapy in Follicular Non-Hodgkin's Lymphoma: Focus on Tolerability

The document reviewed the challenges and strategies of salvage chemotherapy in treating relapsed follicular non-Hodgkin's lymphoma (FL), focusing on the tolerability of various regimens. It highlighted significant short- and long-term toxicities, such as myelosuppression, febrile neutropenia, hemorrhage, and impaired quality of life. The use of rituximab in combination with chemotherapy showed promise in improving overall survival and reducing the need for repeated cycles. The review emphasized the importance of balancing efficacy with tolerability, especially in elderly patients, and noted the potential benefits of maintenance therapies like rituximab in prolonging remission and enhancing long-term outcomes.